What this means for cost
CagriSema has no price yet: Novo has not announced one, and it cannot be sold until the FDA approves it. If you want to start now, these are today's prices for the closest options, from the dated reads on our board and the makers' own self-pay pages.
- Wegovy (semaglutide) from Novo, self-pay$199 to $399/moby dose, the maker's published self-pay price; offer terms on the price tracker pageRead 14 Nov 2026.
- Cheapest Wegovy through a program we track$208/moat Sesame Care, an average: a $59/mo subscription billed $708 once a year, with medication billed monthly, all inSesame Care: plans and pricesRead 22 Nov 2026.
- Cheapest compounded semaglutide$39/moat Wellmedr, sale price, all inWellmedr: plans and pricesRead 22 Nov 2026. Compounded, not FDA-approved.
- Zepbound (tirzepatide) from Lilly, self-pay$299 to $449/moby dose, the maker's published self-pay price; offer terms on the price tracker pageRead 14 Nov 2026.
Compounded drugs are not FDA-approved. Products sold online as "compounded CagriSema" are not the drug in Novo's trials.
What happens next
- Q4 2026 (by Dec 31, 2026)FDA decision expected, per Novo. We will update this page the day it is announced.
- Early 2027Novo's planned US launch, if the FDA approves it.
- H1 2027REDEFINE 11 phase 3 results, per Novo's milestone table.




